ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has signed a three-year agreement with Pfizer Inc. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.
The new agreement builds on the companies’ existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.
Ciaran Murray, ICON’s CEO, commented: "The progression of our relationship with Pfizer is a recognition of ICON’s capabilities in supporting drug development efforts. We look forward to continuing our relationship with Pfizer to help advance its development pipeline and innovation in the drug development process.”